Human genetic variation and personalized medicine.

Human genome sequencing results revealed an insight into the role of human genetic variation behind differential susceptibility of human diseases, differential response to pharmacological agents and presence of varied phenotypes. This leads to the concept of personalized medicine. In the present review we have discussed the objectives and approaches for carrying out pharmacogenomics and pharmacogenetics studies. The review also incorporates the major findings categorizing the common diseases on the basis of genetic profiles and ethnic information and in establishing personalized disease diagnosis, drug responses and treatment modalities based on the genetic determinants. Overall an attempt has been made to highlight the importance of studying the genetic profiles of an individual in biomedical and pharmacogenomics research.

Exercise tolerance test: a comparison between true positive and false positive test results

To study the factors which predetermine the coronary artery disease in patients having positive Exercise Tolerance Test [ETT] after comparing the ETT test results and coronary angiographic findings in true positive and false positive groups. This Cross-sectional study was conducted at Punjab Institute of Cardiology, Lahore from January 1, 2004 to December 31, 2004. All patients who had ETT done for chest pain diagnosis were studied. Patients were advised coronary angiography if ETT was positive for exercise induced ischaemia. One hundred and forty eight patients had coronary angiography done after positive ETT. Patients were divided into two groups depending upon the angiographic findings, i.e., true positive and false positive. Both groups were compared with each other. Results: Out of 148 patients, 126 [85.1%] patients had true positive ETT and 22 [14.9%] patients had false positive ETT. The mean age of patients in true positive group was 48.96 +/- 9.08 years and 50.9 +/- 7.85 years in false positive group. One hundred and eighteen [93.7%] male patients and 8 [6.3%] female patients had true positive ETT, whereas 14 [63.6%] males and 8 [36.4%] females had false positive ETT [p < 0.0001]. There was no statistically significant difference in the two groups in comparison of age and other conventional risk factors like diabetes mellitus, hypertension, smoking, family history and dyslipidemia. Abnormal resting ECG had a statistically significant difference between the groups [p < 0.04], likewise is hypertensive haemodynamic response during ETT [p < 0.003]. The symptom limited ETT as compared to no symptoms during ETT also conferred a statistically significant difference between the groups [p<0.0001]. Strongly positive ETT was also associated with true positive ETT [p < 0.002]. Amongst the vessels involved the most common was the LAD 113 [89.7%], followed by LCX 80 [63.5%] and the RCA 72 [57.1%]. Most of the patients 51 [40.5%] had three vessel disease as compared to SVD 34 [27%]. It can be concluded that amongst the patients who have positive ETT, females with abnormal resting ECG, who achieve target heart rate and have a hypertensive haemodynamic response with no symptoms are likely to have a false positive test result. Conversely male patients with normal resting ECG who do not achieve target heart rate, have a normotensive haemodynamic response and a strongly positive, symptom limited ETT are likely to have a true positive treadmill test result

Warfarin use has no effect on blood pressure of patients with Diabetes and hypertension / Uso da warfarina não tem efeitos sobre a pressão arterial em pacientes com diabetes e hipertensão arterial sistêmica

Introduction: Warfarin causes arterial calcification, arterial stiffness and systolic hypertension in animals. Early evidence in humans indicates that a similar effect may occur in patients with diabetes mellitus (DM) and/or hypertension. Objective: To evaluate whether warfarin use causes elevated blood pressure and pulse pressure in patients with both DM and hypertension. Methods: Cross-sectional study of 159 subjects with both DM and hypertension who received warfarin for at least 2 years and 159 age-matched control subjects with DM and hypertension never exposed to warfarin. The primary focus of analysis was the difference in systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse pressure (PP) between the two groups. Results: Average age was 73±10 years in both groups. Patients in the warfarin group had received it for an average of 5.5±3.1 years. Subjects in the warfarin group had higher rates of coronary disease and heart failure. SBP and PP were lower in the warfarin group (SBP 130±14 mmHg vs. 134±12 mmHg, P=0.003; PP 58±12 mmHg vs. 62±11 mmHg, P=0.004), while DBP was not different (72±8 vs. 72±7 mmHg, P=0.64). Warfarin patients received more antihypertensive drugsand were seen more often than controls. Multiple regression analyses adjusting for relevant variables did not disclose an association between warfarin useand higher BP; on the contrary, exposure to warfarin was associated with lower SBP and PP on the multivariable models. Conclusion: Use of warfarin in conventional doses for an average of 5.5 years was not associated with increased BP in this cross-sectional study of patients with DM and hypertension.

Introdução: Em animais, a warfarina provoca calcificação arterial, rigidez arterial e hipertensão arterial (HA) sistólica. Dados preliminares em humanos sugerem que o mesmo efeito pode acontecer em pacientes com diabetes mellitus (DM) e/ou HA. Objetivo: Determinar se o uso da warfarina em pacientescom DM e HA resulta em elevação da pressão arterial ou pressão de pulso. Métodos: Estudo transversal de 159 pacientes com DM e HA que haviam sidotratados com warfarina por pelo menos 2 anos, e 159 controles pareados por idade, com DM e HA, mas que nunca haviam usado warfarina. O enfoqueprincipal na análise foi a diferença na pressão arterial sistólica (PAS), diastólica (PAD) e pressão de pulso (PP) entre os dois grupos. Resultados: A média de idade foi 73±10 anos em ambos os grupos. Os pacientes no grupo da warfarina haviam usado a droga por 5.5±3.1 anos. Pacientes no grupo da warfarina tinham uma prevalência maior de doença coronariana e insuficiência cardíaca. A PAS e PP foram mais baixas no grupo warfarina (PAS 130±14 mmHgvs. 134±12 mmHg, P=0.003; PP 58±12 mmHg vs. 62±11 mmHg, P=0.004), mas a PAD não diferiu entre os grupos (72±8 vs. 72±7 mmHg, P=0.64).Pacientes do grupo warfarina usaram mais drogas antihipertensivas e foram avaliados clinicamente com maior freqüência do que os controles. Regressão múltipla ajustada para fatores de relevância clínica não demonstrou nenhuma associação entre o uso da warfarina e elevação da pressão arterial. Pelo contrário, nos modelos de regressão múltipla, a exposição à warfarina associou-se a valores mais baixos de PAS e PP. Conclusão: O uso da warfarina em doses convencionais, por 5.5 anos, não associou-se a um aumento da pressão arterial neste estudo tranversal de pacientes com DM e hipertensão.

S252W mutation in Indian patients of Apert syndrome.

Two common mutations in the exon IIIa of fibroblast growth factor receptor 2 account for majority of the cases of Apert syndrome. They can be analyzed by amplifying the segment followed by testing for the abolition of restriction sites. We evaluated two children with typical features of Apert syndrome. A segment of FGFR2 exon IIIa was amplified by polymerase chain reaction. Restriction fragment length polymorphism was analyzed using enzymes MboI and BglI respectively for S252W and P253R mutations. The DNA segment was sequenced using ABI 310 automated DNA fragment analyzer. Both the patients showed S252W mutations. DNA sequencing confirmed the results of the restriction fragment length polymorphism. Our study is the first report from Indian subcontinent to show the prevalence of S252W mutation among Apert syndrome patients from Indian origin.

Short tandem repeat technology has diverse applications: individual identification, phylogenetic reconstruction and chimerism based post haematopoietic stem cell transplantation graft monitoring.

BACKGROUND: Short Tandem Repeat (STR) loci are widely considered to be effective for variety of applications including forensic applications, phylogenetic reconstruction and chimerism based post Haematopoietic Stem Cell Transplantation (HSCT) graft monitoring. For each application, specific sets of STR loci are used. AIMS: In the present study, we have attempted to use same set of STR loci for varied purposes based on their efficacy and informativity. SETTINGS AND DESIGN: Population and patient based study. MATERIALS AND METHODS: We have analyzed 5 STR loci--vWA, Tho1, FES, F13 and TPOX in 1000 North Indians. All five markers were also analyzed for chimerism based graft monitoring after HSCT in 42 HLA matched pair of patient-donor to predict the outcome of transplantation. STATISTICAL ANALYSIS: The analysis was done for Hardy Weinberg equilibrium (HWE), Heterozygosity, Polymorphism information content (PIC) and Power of Exclusion and Phylogenetic assessment. RESULTS AND CONCLUSIONS: High allelic variability in term of Heterozygosity (0.68-0.76), PIC (0.66-0.74) and high Power of exclusion (0.28-0.38) indicating high forensic utility. The ensuing PC plots finely resolved three basal clusters corresponding to three geo-ethnic groups of African, Orientals, and Caucasians. In post HSCT chimerism analysis, it was found that together these markers were informative in 38 pairs (98%) and were able to predict the chimerism status successfully. There is a possibility that these STR loci along with forensic and phylogenetic importance, can predict the outcome of HSCT successfully.

Association of human leucocyte DR and DQ antigens in Crohn's disease in Asian Indians: a family study.

The pathogenesis of Crohn's disease (CD) involves an abnormal immune response to enteric bacteria in genetically susceptible individuals. There are no family studies regarding the association of CD with human leucocyte antigens (HLA) class II. In the present study, we have studied the association of HLA class II antigens in patients with CD and their first-degree relatives. Nine patients with CD and their first-degree relatives were studied. A group of 110 healthy unrelated and ethnically matched subjects were used as controls. Molecular HLA typing was done using the sequence-specific primer-based method. The transmission disequilibrium test (TDT) was used to analyze the results. A total of 65 individuals were included in the study; 52/56 first-degree relatives (92.8%) of 9 patients with CD consented to the study. The median age of patients was 40 years. When the distribution of the HLA class II antigens in patients was compared to that in controls no significant differences were observed even after applying the Yates correction. As the sample size of the population was small, the association of CD with DR and DQ alleles was further analyzed by using the TDT. Even after applying TDT, no significant association was observed. Familial aggregation of CD is uncommon in India. Crohn disease is not associated with HLA class II antigens in Indian patients. Genes of the major histocompatiblity complex are likely to contribute little to the susceptibility to Crohn disease in Indian patients.

Polymorphisms in the apolipoprotein B-100 gene: association with plasma lipid concentration and coronary artery disease.

BACKGROUND: The aim of this study was to investigate the association of apolipoprotein B gene polymorphisms with coronary artery disease and lipid levels in Indians. METHODS AND RESULTS: One hundred patients of angiographically proven atherosclerotic coronary artery disease and one hundred age- and sex-matched control subjects (treadmill negative) were included in the study. Serum lipids including cholesterol, triglycerides, high-density lipoprotein, low-density lipoprotein, very low-density lipoprotein, and apolipoprotein B were analyzed. Genomic DNA was extracted and the apolipoprotein B 3' hypervariable region amplified by polymerase chain reaction. Regions carrying Xba1, EcoR1, and Msp1 restriction sites present in the apolipoprotein B gene were amplified and digested separately by the respective enzymes. Restriction fragment length polymorphism analysis showed that EcoR1 with the R+/R+ genotype was significantly more common in patients with coronary artery disease. Overall, the genotypes EcoR1+/+, Msp1+/+, Xba1+/+ and Eco R1+/+ Msp1+/-, Xba1-/- were significantly more common in patients as compared to controls (p<0.05). When gene polymorphisms were compared with lipid abnormalities, the genotypes EcoR1+/+, Xba1-/-, and Msp1+/+ were more frequent in patients with elevated apolipoprotein B and very low-density lipoprotein levels. On the other hand, these genotypes were less common in patients with increased total cholesterol and low-density lipoprotein levels. When we studied the individual alleles of the variable number of tandem repeats region, we observed that allele 34 was significantly increased in patients with coronary artery disease as compared to controls. Allele 36 was present with a frequency of 1% in controls while it was totally absent in patients. CONCLUSIONS: This study identifies the apolipoprotein B gene polymorphism associated with coronary artery disease. An association between apolipoprotein B gene polymorphisms and elevated apolipoprotein B and very low-density lipoprotein levels was observed. However, there was no positive association with other elevated lipid levels in North Indians from Uttar Pradesh.